Ultragenyx Pharmaceutical Inc. (RARE) Financial Statements
Ultragenyx Pharmaceutical Inc. (RARE) reported trailing twelve-month revenue of $717.2M (up 17.5% year on year) and net income of -$586.0M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$489.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RAREUltragenyx Pharmaceutical Inc.Follow RARE — free
—
Price chart with a free account
- Market cap
- 1.5B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.05 | 0.10 | 0.27 | 0.35 | 0.36 | 0.43 | 0.56 | 0.67 | 0.72 | |
| Gross profit | 0.00 | 0.05 | — | — | — | — | 0.39 | 0.48 | 0.56 | 0.60 | |
| Research & development | 0.23 | 0.29 | 0.36 | 0.41 | 0.50 | 0.71 | 0.65 | 0.70 | 0.75 | 0.77 | |
| Operating income | -0.33 | -0.37 | -0.42 | -0.33 | -0.38 | -0.65 | -0.57 | -0.54 | -0.54 | -0.53 | |
| Pre-tax income | -0.32 | -0.20 | -0.40 | -0.19 | -0.45 | -0.70 | -0.61 | -0.57 | -0.57 | -0.58 | |
| Income tax | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | -0.00 | 0.00 | 0.00 | 0.00 | |
| Net income | -0.30 | -0.20 | -0.40 | -0.19 | -0.45 | -0.71 | -0.61 | -0.57 | -0.58 | -0.59 | |
| Diluted EPS ($) | -7.12 | -3.97 | -7.12 | -3.07 | -6.70 | -10.12 | -8.25 | -6.29 | -5.83 | -5.83 | |
| Diluted shares (bn) | — | — | — | — | — | 0.070 | 0.073 | 0.090 | 0.099 | — |
USD billions · SEC XBRL
Ultragenyx Pharmaceutical Inc. — questions
- What is Ultragenyx Pharmaceutical Inc.'s revenue?
- $717.2M over the twelve months to 2026-06-30, up 17.5% year on year, from its 10-Q and 10-K filings.
- What is Ultragenyx Pharmaceutical Inc.'s net income?
- -$586.0M over the twelve months to 2026-06-30.
- What is Ultragenyx Pharmaceutical Inc.'s free cash flow?
- -$489.0M over the twelve months to 2026-06-30.
- What are Ultragenyx Pharmaceutical Inc.'s diluted earnings per share?
- $-5.83 over the twelve months to 2026-06-30.
Every figure on this page comes from Ultragenyx Pharmaceutical Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.